| Quarterly Financials | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
Revenue  | 251 | 217 | 282 | 190 | 211 | 254 | 247 | 296 | 281 | 293 | 324 | 456 | 381 | 350 | 289 | 367 | 381 | 358 | 251 | 234 | 270 | 508 | 620 | 698 | 853 | 564 | 571 | 551 |
| Expenses | 129 | 95 | 147 | 99 | 108 | 126 | 140 | 138 | 166 | 149 | 179 | 206 | 207 | 188 | 179 | 207 | 198 | 181 | 133 | 154 | 180 | 363 | 398 | 439 | 627 | 445 | 435 | 454 |
| EBITDA | 122 | 122 | 135 | 91 | 103 | 128 | 107 | 158 | 116 | 144 | 144 | 251 | 174 | 162 | 111 | 160 | 183 | 178 | 118 | 80 | 90 | 145 | 222 | 259 | 226 | 118 | 137 | 97 |
| Operating Profit % | 49 % | 52 % | 46 % | 45 % | 41 % | 47 % | 41 % | 50 % | 36 % | 43 % | 40 % | 48 % | 43 % | 45 % | 36 % | 41 % | 47 % | 48 % | 42 % | 30 % | 29 % | 26 % | 34 % | 35 % | 25 % | 19 % | 22 % | 17 % |
| Depreciation | 6 | 6 | 6 | 6 | 7 | 7 | 8 | 9 | 8 | 9 | 9 | 11 | 10 | 12 | 12 | 12 | 12 | 13 | 12 | 13 | 17 | 31 | 38 | 44 | 54 | 45 | 44 | 47 |
| Interest | 2 | 4 | 4 | 8 | 7 | 3 | 3 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 0 | 1 | 5 | 1 | 1 | 2 | 2 | 10 | 10 | 11 | 10 | 10 | 9 | 9 |
| Profit Before Tax | 115 | 113 | 125 | 78 | 89 | 118 | 97 | 148 | 106 | 133 | 134 | 240 | 161 | 149 | 99 | 146 | 166 | 164 | 105 | 66 | 71 | 103 | 174 | 205 | 161 | 63 | 84 | 41 |
| Tax | 40 | 21 | 32 | 20 | 15 | 26 | 23 | 34 | 22 | 28 | 37 | 79 | 70 | 41 | 26 | 38 | 42 | 43 | 26 | 19 | 18 | 28 | 36 | 51 | 44 | 16 | 17 | 12 |
| Net Profit | 75 | 92 | 93 | 58 | 74 | 92 | 74 | 114 | 83 | 105 | 97 | 160 | 92 | 108 | 72 | 108 | 124 | 121 | 80 | 47 | 53 | 75 | 138 | 154 | 117 | 46 | 66 | 29 |
| EPS in ₹ | 5.88 | 7.22 | 3.65 | 4.55 | 5.83 | 3.60 | 2.91 | 4.46 | 3.27 | 4.13 | 3.81 | 6.29 | 3.60 | 4.22 | 2.83 | 4.23 | 4.87 | 4.74 | 3.13 | 1.84 | 2.10 | 1.98 | 3.63 | 4.02 | 3.16 | 1.28 | 1.94 | 0.96 |
Cohance Lifesciences
Cohance Lifesciences
309.95
+1.60
(0.52%)
Market Cap
11,857.67 Cr
PE Ratio
45.52
Volume
12,13,458.00
Day High - Low
314.10 - 303.10
52W High-Low
1,250.00 - 303.05
Key Fundamentals
Market Cap
11,857.67 Cr
EPS
10.52
PE Ratio
45.52
PB Ratio
3.11
Book Value
99.01
EBITDA
433.80
Dividend Yield
0.00 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
14.38
Debt to Equity
0.09
Analyst Rating and Forecast
- By Refinitiv from8 analysts
Actual
Company News
View All News
JASUB Property Holdings LLP acquired 70,00,000 shares (1.83%) of Cohance Lifesciences through inter-se transfer block deals on February 18, 2026, as disclosed under SEBI regulations.
Jasti Property and Equity Holdings Private Limited, acting as trustee of Jasti Family Trust, disclosed a reduction in shareholding in Cohance Lifesciences Limited from 6.59% to 6.36% through open market and inter-se transfer transactions.
Cohance Lifesciences Limited has made available the audio recording of its quarterly conference call for Q3FY26 and nine months ended December 31, 2025, on its website.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,737.00 | #1 4,16,764.48 | 39.09 | #1 54,729.00 | 9.71 | #1 10,980 | 16.07 | 55.50 | |
6,408.50 | 1,70,125.54 | 69.29 | 9,712.00 | 18.67 | 2,191 | -1.02 | 57.58 | |
4,333.30 | 1,46,658.56 | 65.55 | 11,539.40 | 6.99 | 1,911 | 26.24 | 65.06 | |
1,348.20 | 1,08,903.79 | 24.19 | 28,409.50 | 7.12 | 5,291 | -57.18 | 47.64 | |
1,286.30 | 1,07,358.50 | 19.93 | 33,741.20 | 16.73 | 5,725 | -15.28 | 55.60 | |
2,301.90 | 1,05,150.52 | 22.74 | 22,909.50 | 13.74 | 3,306 | #1 37.44 | 66.87 | |
2,247.60 | 92,782.07 | 52.20 | 12,744.20 | #1 20.90 | 2,007 | 7.65 | 63.52 | |
921.70 | 92,744.59 | #1 18.78 | 23,511.00 | 18.55 | 4,615 | -0.32 | 55.01 | |
1,220.40 | 70,881.03 | 20.37 | 32,345.60 | 9.43 | 3,484 | 7.59 | 58.41 | |
5,639.50 | 67,428.68 | 28.38 | 13,458.30 | 3.70 | 2,216 | 1.90 | 51.36 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
12.83 %
Net Income Growth
-11.82 %
Cash Flow Change
-19.62 %
ROE
-1.78 %
ROCE
-30.56 %
EBITDA Margin (Avg.)
-17.81 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 783 | 1,173 | 1,475 | 1,830 | 1,966 | 2,254 | 3,032 |
| Fixed Assets | 271 | 357 | 441 | 534 | 663 | 670 | 1,713 |
| Current Assets | 390 | 392 | 565 | 1,128 | 1,011 | 1,263 | 889 |
| Capital Work in Progress | 111 | 102 | 96 | 30 | 165 | 179 | 256 |
| Investments | 7 | 338 | 542 | 598 | 536 | 905 | 337 |
| Other Assets | 394 | 376 | 395 | 667 | 601 | 501 | 726 |
| Total Equity & Liabilities | 783 | 1,173 | 1,475 | 1,830 | 1,966 | 2,254 | 3,032 |
| Current Liabilities | 158 | 200 | 220 | 210 | 159 | 107 | 365 |
| Non Current Liabilities | 35 | 128 | 74 | 92 | 72 | 97 | 826 |
| Total Equity | 590 | 845 | 1,181 | 1,527 | 1,735 | 2,051 | 1,841 |
| Reserve & Surplus | 578 | 832 | 1,155 | 1,502 | 1,710 | 2,025 | 1,671 |
| Share Capital | 13 | 13 | 26 | 26 | 26 | 26 | 26 |
Cash Flow
| Cash Flow | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 11 | 1 | -5 | 37 | 20 | -18 | 38 |
| Investing Activities | -66 | -414 | -311 | -136 | -195 | -362 | -253 |
| Operating Activities | 50 | 407 | 383 | 330 | 457 | 359 | 288 |
| Financing Activities | 26 | 7 | -76 | -156 | -242 | -14 | 3 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | May 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
| Promoter | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 50.10 % | 50.10 % | 50.10 % | 50.10 % | 50.10 % | 66.41 % | 66.41 % | 57.49 % | 57.49 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 10.01 % | 10.14 % | 9.54 % | 9.80 % | 10.70 % | 10.84 % | 11.05 % | 7.38 % | 7.23 % | 6.51 % | 6.02 % |
| DIIs | 4.30 % | 4.47 % | 4.94 % | 5.24 % | 5.91 % | 6.32 % | 10.52 % | 11.35 % | 11.43 % | 9.23 % | 14.14 % | 15.94 % | 17.24 % | 17.42 % | 16.94 % | 16.68 % | 16.60 % | 11.02 % | 11.40 % | 20.82 % | 21.57 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % |
| Public / Retail | 20.87 % | 19.86 % | 19.21 % | 18.38 % | 17.07 % | 16.86 % | 14.69 % | 14.01 % | 12.76 % | 12.80 % | 11.76 % | 10.87 % | 10.51 % | 10.08 % | 9.75 % | 9.81 % | 9.68 % | 6.63 % | 6.40 % | 6.42 % | 6.76 % |
| Others | 14.84 % | 15.68 % | 15.86 % | 16.38 % | 17.02 % | 16.82 % | 14.78 % | 14.64 % | 15.81 % | 17.97 % | 4.08 % | 3.04 % | 12.59 % | 12.59 % | 12.50 % | 12.56 % | 12.55 % | 8.55 % | 8.55 % | 8.75 % | 8.16 % |
| No of Share Holders | 75,207 | 92,534 | 96,532 | 86,447 | 85,725 | 86,088 | 82,577 | 79,412 | 72,885 | 72,167 | 73,715 | 70,052 | 68,932 | 65,777 | 69,337 | 84,210 | 86,325 | 88,658 | 80,910 | 75,284 | 81,877 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 5 | 2 | 5 | 6 | 0.00 | 0.00 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 1.01 | 0.32 | 1.06 | 0.89 | 0.00 | 0.00 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 28 Sept 2020 |  Bonus | 1:1 | 25 Sept 2020 | 383.55 | 383.70 |
| 18 Feb 2021 |  Dividend | ₹ 1.00 /share | 17 Feb 2021 | 486.60 | 494.65 |
| 17 Aug 2021 | Dividend | ₹ 1.00 /share | 13 Aug 2021 | 514.80 | 559.70 |
| 16 Feb 2022 | Dividend | ₹ 1.00 /share | 15 Feb 2022 | 558.50 | 522.45 |
| 16 Feb 2022 | Dividend | ₹ 2.00 /share | 15 Feb 2022 | 558.50 | 522.45 |
| 17 May 2022 | Dividend | ₹ 1.00 /share | 13 May 2022 | 580.15 | 507.45 |
| 17 May 2022 | Dividend | ₹ 1.00 /share | 13 May 2022 | 580.15 | 507.45 |
| 12 Sept 2022 | Dividend | ₹ 5.00 /share | 09 Sept 2022 | 492.90 | 477.85 |
| 12 Sept 2022 | Dividend | ₹ 1.00 /share | 09 Sept 2022 | 492.90 | 477.85 |
| 15 Dec 2023 |  Annual General Meeting | NA | 15 Dec 2023 | 572.10 | 673.25 |
| 09 Aug 2024 | Annual General Meeting | NA | 09 Aug 2024 | 848.75 | 990.80 |
| 12 Nov 2024 |  Quarterly Result Announcement | NA | 12 Nov 2024 | 1,197.40 | 1,250.60 |
| 28 Nov 2024 |  Extraordinary General Meeting | NA | 28 Nov 2024 | 1,266.90 | 1,259.05 |
| 12 Feb 2025 | Quarterly Result Announcement | NA | 12 Feb 2025 | 1,148.20 | 1,084.55 |
| 07 May 2025 |  Change Of Name | NA | 07 May 2025 | 1,118.50 | 1,118.50 |
| 28 May 2025 | Quarterly Result Announcement | NA | 28 May 2025 | 1,151.25 | 1,092.20 |
| 13 Aug 2025 | Quarterly Result Announcement | NA | 13 Aug 2025 | 1,002.00 | 949.95 |
| 19 Sept 2025 | Annual General Meeting | NA | 19 Sept 2025 | 980.00 | 912.70 |
| 12 Nov 2025 | Quarterly Result Announcement | NA | 12 Nov 2025 | 869.30 | 691.30 |
| 12 Feb 2026 | Quarterly Result Announcement | NA | 12 Feb 2026 | 537.60 | 355.05 |
Announcements
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
3 days ago
3 days agoDisclosures under Reg. 29(1) of SEBI (SAST) Regulations 20117 days ago
7 days agoDisclosures under Reg. 29(2) of SEBI (SAST) Regulations 20117 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation7 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 16, 2026
Feb 16, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 13, 2026
Feb 13, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 12, 2026
Feb 12, 2026Announcement under Regulation 30 (LODR)-Investor PresentationFeb 12, 2026
Feb 12, 2026Outcome Of Board MeetingFeb 12, 2026
Feb 12, 2026Board Meeting Outcome for Outcome Of Board MeetingFeb 12, 2026
Feb 12, 2026Cohance Lifesciences Limited Has Informed The Exchange About Additional Information On USFDA Announcement.Feb 06, 2026
Feb 06, 2026Cohance Lifesciences Limited Has Informed The Exchange About USFDA Announcement.Feb 04, 2026
Feb 04, 2026Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance OfficerFeb 02, 2026
Feb 02, 2026 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJan 22, 2026
Jan 22, 2026Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotJan 22, 2026
Jan 22, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 22, 2026
Jan 22, 2026Announcement under Regulation 30 (LODR)-Change in ManagementJan 19, 2026
Jan 19, 2026Grant Of Stock OptionsJan 17, 2026
Jan 17, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 05, 2026
Jan 05, 2026Closure of Trading WindowDec 29, 2025
Dec 29, 2025Board Meeting Intimation for Considering The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Nine-Months Ending December 31 2025Dec 29, 2025
Dec 29, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationDec 29, 2025
Dec 29, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationDec 24, 2025
Dec 24, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotDec 23, 2025
Dec 23, 2025Intimation Of Change In Website Address Of The CompanyDec 13, 2025
Dec 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 13, 2025
Dec 13, 2025Announcement under Regulation 30 (LODR)-Change in ManagementDec 05, 2025
Dec 05, 2025Announcement under Regulation 30 (LODR)-Credit RatingDec 03, 2025
Dec 03, 2025Grant Of Stock OptionsDec 03, 2025
Dec 03, 2025General UpdatesDec 02, 2025
Dec 02, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 28, 2025
Nov 28, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 24, 2025
Nov 24, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 17, 2025
Nov 17, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 14, 2025
Nov 14, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 12, 2025
Nov 12, 2025Announcement under Regulation 30 (LODR)-Investor PresentationNov 12, 2025
Nov 12, 2025Outcome Of The MeetingNov 12, 2025
Nov 12, 2025Board Meeting Outcome for Outcome Of The Board MeetingNov 12, 2025
Nov 12, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 05, 2025
Nov 05, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 05, 2025
Nov 05, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 01, 2025
Nov 01, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeOct 28, 2025
Oct 28, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateOct 28, 2025
Oct 28, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 28, 2025
Oct 28, 2025General UpdateOct 26, 2025
Oct 26, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 08, 2025
Oct 08, 2025Closure of Trading WindowSep 27, 2025
Sep 27, 2025Board Meeting Intimation for Considering And Approval Of The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Half Year Ending September 30 2025.Sep 27, 2025
Sep 27, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 24, 2025
Sep 24, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Sep 22, 2025
Sep 22, 2025Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 29.12
ATR(14)
Less Volatile 18.26
STOCH(9,6)
Oversold 18.70
STOCH RSI(14)
Overbought 96.41
MACD(12,26)
Bullish 2.84
ADX(14)
Very Strong Trend 51.90
UO(9)
Bearish 36.37
ROC(12)
Downtrend And Accelerating -10.98
WillR(14)
Oversold -88.07
About Cohance Lifesciences
Suven Pharmaceuticals Limited is an Indian biopharmaceutical company incorporated in 2018. It specializes in contract development and manufacturing operations for the global life sciences industry, focusing on New Chemical Entity-based intermediates, Active Pharmaceutical Ingredients, specialty chemicals, and formulated drugs. The company provides custom synthesis, process R&D, scale-up, and contract manufacturing...more
Website
Chairperson NameVivek Sharma
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
